ArticleCureus2025
Impact of Enoxaparin on Maternal and Fetal Outcomes in In Vitro Fertilization (IVF) Pregnancies With Thyroid Autoimmunity: A Real-World, Single-Center, Retrospective, Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim Thyroid autoimmunity (TAI) in women undergoing in vitro fertilization (IVF) is linked to adverse pregnancy outcomes, despite euthyroid status. This study aims to evaluate the efficacy of enoxaparin in improving maternal and fetal outcomes in anti-thyroid antibody (ATA)-positive euthyroid IVF pregnancies. Methods This observational study included 80 ATA-positive women undergoing IVF. Levothyroxine was administered in hypothyroid women to achieve euthyroid status prior to embryo transfer, and enoxaparin therapy was initiated post-transfer and continued throughout pregnancy. The primary outcome was live birth rate. Secondary outcomes included obstetric complications - pregnancy-induced hypertension (PIH), gestational diabetes mellitus (GDM), intrauterine growth restriction (IUGR), miscarriage, and preterm delivery. Results The live birth rate was 78 (97.5%). Among single pregnancies, 44 (95.7%) reached full term, with only two (4.4%) resulting in preterm births. Twin pregnancies had a higher preterm birth rate of 11 (39.3%). The incidence of PIH was 11 (34.2%), with higher rates in twin pregnancies, seven (25.9%), compared to single pregnancies, four (8.3%). GDM was equally prevalent in both single and twin pregnancies (13 (26%) vs. 6 (21.4%)). A miscarriage was observed in two of the total cases. IUGR affected two (4.2%) of singleton and two (7.4%) of twin pregnancies. First-trimester bleeding occurred in five (10%) of singleton and three (10.7%) of twin pregnancies, while only one (3.6%) case of placental abruption was observed in twin pregnancies. No major safety concerns were observed. Conclusion Enoxaparin was associated with improved maternal and fetal outcomes, notably reducing the rates of miscarriage, preterm birth, and IUGR. These findings suggest that enoxaparin can be a valuable addition for improving pregnancy outcomes in ATA-positive patients undergoing IVF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.